Auckland City Hospital
Auckland, New Zealand
27 recruiting
Showing 1–20 of 68 trials
Recruiting
Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines500 enrolled77 locationsNCT07277231
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled244 locationsNCT06935357
Recruiting
Phase 3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited520 enrolled31 locationsNCT06520345
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
Neonatal EncephalopathyNeonatal SeizureSeizure Newborn+1 more
University of California, San Diego133 enrolled5 locationsNCT05610085
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled475 locationsNCT06531824
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled332 locationsNCT07028853
Recruiting
Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Endometrial Cancer
Canadian Cancer Trials Group393 enrolled110 locationsNCT05640999
Recruiting
Not Applicable
Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation
Atrial Fibrillation
French Cardiology Society250 enrolled9 locationsNCT07462910
Recruiting
Phase 3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Boehringer Ingelheim670 enrolled236 locationsNCT07472517
Recruiting
Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines310 enrolled52 locationsNCT06596473
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled173 locationsNCT06943872
Recruiting
Not Applicable
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Coronary Arterial Disease (CAD)de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation1,616 enrolled55 locationsNCT06959524
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring84 enrolled98 locationsNCT07332091
Recruiting
Phase 1
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines392 enrolled46 locationsNCT06427941
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Advanced Solid TumorSolid Tumor
BeOne Medicines217 enrolled28 locationsNCT05981703
Recruiting
Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Hodgkin Lymphoma
University College, London1,042 enrolled71 locationsNCT04685616